Based on the docking score and commercial availability, eight drug candidates were chosen from the in silico screening for in vitro evaluation in NSCLC-bearing wild-type EGFR, EGFR L858R (sensitizing mutation), or EGFR L858R/T790M (resistance-causing mutation). Here, EGFR is linked to non-small cell lung carcinoma.